Bioharmony Therapeutics is developing a topical antibiotic to treat gram negative, multi-drug resistant A.baumannii in wounds and burns. The species is an opportunistic pathogen which is particularly threatening to hospitals and burn wards. It has been listed by the WHO as a priority target with a critical need for new therapeutics.
PainQx is developing a diagnostic to quantify pain. It utilizes a standard EEG headset to perform a rapid reading that is processed by a proprietary, cloud-hosted algorithm. The company is targeting the clinical research and clinical markets.
Concarlo Holdings is developing a therapeutic and companion diagnostic for ER+ HER2- breast cancer patients. The current standard of care is a new class of drugs called cdk4 inhibitors. Only ~50% of patients respond, and many develop resistance. Concarlo's diagnostic screens for cdk4 inhibitor therapy receptivity in the standard biopsy panel. Their therapeutic is an improved cdk4 inhibitor that blocks the pathway leading to resistance.
ENB is developing a product to be used in combination with PD-1/PD-L1 immunotherapies. These immunotherapies are highly effective, but only in 15-20% of patients due to the lack of PD-1/PD-L1 expression by the tumor. ENB's lead product restores TIL (tumor infiltrating lymphocytes) infiltration into tumors, promoting expression of these receptors, and transforming the tumor to be receptive to PD-1/PD-L1 immunotherapies.
Targagenix is developing a chemotherapy agent with significantly improved efficacy and reduced systemic toxicity. The compound is a nano-formulated, novel taxane designed to evade the common chemotherapy resistance pathways. The product is effective in numerous cancer types and has been shown to have synergy with PD-1/PD-L1 immunotherapy agents.
EpiVax Oncology is leveraging a proprietary computational platform, called Ancer, to design highly effective personalized cancer vaccines. A biopsy of a patient’s tumor is sequenced to elucidate specific mutations (called the mutanome). Ancer analyzes the mutanome to predict the most effective immuno-stimulatory epitopes.
Mymee is a digital therapeutic company targeting chronic auto-immune disease. The platform combines an app for patient self reporting, a machine-learning analysis algorithm to extract causative and related triggers, and professional health tele-coaching to support the patient in modifying their behaviors.
Paladin is building a first-to-market, global, pro bono platform to host case opportunities and facilitate adoption by corporations and legal firms.
Monogram is developing a platform technology which transform patient diagnostic images (CT Scans) into custom printed titanium orthopedic implants and the milling instructions to guide an orthopedic robot to create the matching cavity. Their first indication is hip implants.
Toggle is developing a Robotics as a Service (RaaS) platform to assemble rebar cages for reinforced concrete in construction applications. Their 2-arm robotic platform and proprietary jig design can build any shape directly from the computer blueprint (CAD or BIM file).
Frenzy is developing an AI brand-specific visual search tool for web-hosted images, targeting the affiliate sales market. The tool auto-tags the images with shoppable links, dramatically increasing sales conversion.
Co-founded by Vanguard Motorcycles, Eric Buell Racing, & Spark Racing Technologies, Vanguard Spark is designing stylish, high performance, competitively priced, electric motorcycles and bicycles for urban commuters.
Chimeron Bio is designing off-the-shelf, personalized immunotherapy treatments for cancer utilizing synthetic nanoparticles to deliver self-replicating RNA.
Digitouch Health is developing the first cuff-less oscillometric blood pressure diagnostic embedded in a smart phone case or bluetooth connected key fob.